Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Glaukos Corporation    GKOS

GLAUKOS CORPORATION

(GKOS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Glaukos : Announces Participation in Stephens Investor Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
10/30/2019 | 03:17pm EST

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stephens Investor Conference on Wednesday, November 13, 2019, at 2:30 p.m. CST in Nashville, TN.

A live audio webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com and will be archived for 90 days.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GLAUKOS CORPORATION
02/06GLAUKOS CORPORATION : to Release Fourth Quarter and Full Year 2019 Financial Res..
BU
02/05GLAUKOS : Financial Statements and Exhibits (form 8-K/A)
AQ
01/15GLAUKOS CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/03GLAUKOS : Announces Participation in J.P. Morgan Healthcare Conference
BU
2019GLAUKOS CORP : Completion of Acquisition or Disposition of Assets, Regulation FD..
AQ
2019GLAUKOS : Completes Acquisition of Avedro, Inc.
BU
2019GLAUKOS : Announces Participation in Piper Jaffray Healthcare Conference
BU
2019GLAUKOS CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2019GLAUKOS : 3Q Earnings Snapshot
AQ
2019GLAUKOS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
More news
Financials (USD)
Sales 2019 241 M
EBIT 2019 -26,2 M
Net income 2019 -28,3 M
Finance 2019 96,5 M
Yield 2019 -
P/E ratio 2019 -93,1x
P/E ratio 2020 -122x
EV / Sales2019 11,7x
EV / Sales2020 8,95x
Capitalization 2 917 M
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 67,13  $
Last Close Price 67,33  $
Spread / Highest target 18,8%
Spread / Average Target -0,30%
Spread / Lowest Target -15,3%
EPS Revisions
Managers
NameTitle
Thomas William Burns President, Chief Executive Officer & Director
William J. Link Chairman
Chris M. Calcaterra Chief Operating Officer
Joseph E. Gilliam CFO, CAO & Senior VP-Corporate Development
L. Jay Katz Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAUKOS CORPORATION23.61%2 917
STRYKER CORPORATION5.53%82 983
SMITH & NEPHEW PLC-0.22%20 785
WRIGHT MEDICAL GROUP N.V.-0.85%3 884
INSPIRE MEDICAL SYSTEMS, INC.9.38%1 900
AXONICS MODULATION TECHNOLOGIES, INC.23.75%1 165